Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Invested Capital (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Invested Capital for 7 consecutive years, with $538.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Invested Capital rose 2.23% to $538.7 million in Q4 2025 year-over-year; TTM through Nov 2025 was $538.7 million, a 2.23% increase, with the full-year FY2025 number at $538.7 million, up 2.23% from a year prior.
  • Invested Capital was $538.7 million for Q4 2025 at Nurix Therapeutics, up from $372.3 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $538.7 million in Q4 2025 to a low of $168.7 million in Q1 2024.
  • A 5-year average of $342.8 million and a median of $342.4 million in 2021 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: soared 747.17% in 2021, then plummeted 38.42% in 2024.
  • Nurix Therapeutics' Invested Capital stood at $342.3 million in 2021, then fell by 11.28% to $303.7 million in 2022, then crashed by 33.98% to $200.5 million in 2023, then surged by 162.85% to $527.0 million in 2024, then rose by 2.23% to $538.7 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Invested Capital are $538.7 million (Q4 2025), $372.3 million (Q3 2025), and $447.6 million (Q2 2025).